The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

It's been a good week for BioNTech SE (NASDAQ:BNTX) shareholders, because the company has just released its latest quarterly results, and the shares gained 3.6% to US$111. It was a moderately negative ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

CureVac N.V., a multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA ...

UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

PEOPLE with head and neck cancer will be given fast-track access to a new “transformative” cancer jab.  The injection targets advanced forms of the devastating disease, giving patients ...

In June 2025, Iovance Biotherapeutics announced that the Journal of Clinical Oncology has published the final analysis from ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain’s GSK and Germany’s CureVac US$740 ...